InNeuroCo has been acquired by Integer
The owners of InNeuroCo has sold the company to Integer (NYSE:ITGR).
Founded in 2014 and headquartered in Pembroke Pines, Florida, InNeuroCo is a leading founder-owned designer and contract manufacturer of ultra-precise, highly engineered neurovascular catheters. InNeuroCo’s primary products are single-use catheters principally used in interventional neurovascular procedures for the treatment of ischemic strokes and aneurysms. Offering turnkey product design and development, supported by comprehensive domestic manufacturing capabilities, InNeuroCo serves as a mission-critical supply partner to the world’s preeminent medical device OEMs.
With approximately US$1.4 billion in annual revenue, Integer is one of the largest medical devices outsource manufacturers in the world, serving the cardiac, vascular, rhythm management and neuromodulation markets.
Oaklins TM Capital in the US served as the exclusive financial advisor to InNeuroCo in its sale to Integer (NYSE:ITGR).
Marc Litzenberg
President and CEO, InNeuroCo
Talk to the deal team
James McLaren
Oaklins TM Capital
Michael S. Goldman
Oaklins TM Capital
Bradley S. Goldstein
Oaklins TM Capital
Related deals
Xiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn moreSaideep Healthcare and Research has raised equity
Saideep Healthcare and Research Private Limited has successfully completed a fundraising. This funding will help Saideep become a leading healthcare brand, offering advanced specialties across the region. The funds from this collaboration will be used to diversify into new and complex specialties, expand infrastructure and meet the growing demand for high-quality healthcare services in Western India.
Learn more